, WHO. World Malaria Report, 2017.

, Guidelines for the treatment of malaria, 2018.

P. Charle, Artesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa), Am J Trop Med Hyg, vol.88, pp.1087-92, 2013.
DOI : 10.4269/ajtmh.12-0290
URL : http://www.ajtmh.org/deliver/fulltext/14761645/88/6/1087.pdf?itemId=/content/journals/10.4269/ajtmh.12-0290&mimeType=pdf&containerItemId=content/journals/14761645

K. Kayentao, Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali, Malar J, vol.8, p.5, 2009.

J. L. Ndiaye, Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria, Malar J, vol.8, p.125, 2009.

P. Sondo, Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial, Malar J, vol.14, p.325, 2015.

R. M. Fairhurst, Artemisinin-resistant malaria: research challenges, opportunities, and public health implications, Am J Trop Med Hyg, vol.87, pp.231-272, 2012.
DOI : 10.4269/ajtmh.2012.12-0025
URL : http://www.ajtmh.org/deliver/fulltext/14761645/87/2/231.pdf?itemId=/content/journals/10.4269/ajtmh.2012.12-0025&mimeType=pdf&containerItemId=content/journals/14761645

S. Yeung, D. Socheat, V. S. Moorthy, and A. J. Mills, Artemisinin resistance on the Thai-Cambodian border, Lancet, vol.374, pp.1418-1427, 2009.

E. Pelfrene, M. H. Pinheiro, and M. Cavaleri, Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency, Int Health, vol.7, pp.239-285, 2015.

C. Funck-brentano and P. Jaillon, Rate-corrected QT interval: techniques and limitations, Am. J. Cardiol, vol.72, pp.17-22, 1993.
DOI : 10.1016/0002-9149(93)90035-b

, Eurartesim, p.24, 2018.

A. European-medicines, , p.24, 2018.

B. Hanboonkunupakarn, Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects, Antimicrob Agents Chemother, vol.58, pp.7340-7346, 2014.

O. T. Mytton, Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria, Am J Trop Med Hyg, vol.77, pp.447-50, 2007.

, Scientific REPORtS |, vol.9, 2019.

, African Network for Clinical Trials of Antimalarial Drugs. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial, Lancet, vol.391, pp.1378-90, 2018.

J. Manning, Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisininpiperaquine for malaria prevention halted for concern over prolonged corrected QT interval, Antimicrob Agents Chemother, vol.58, pp.6056-67, 2014.

N. J. White, Cardiotoxicity of antimalarial drugs, Lancet Infect Dis, vol.7, pp.549-58, 2007.

B. Darpo, Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria, Br. J. Clin. Pharmacol, vol.80, pp.706-721, 2015.

G. O. Adjei, Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunateamodiaquine or artemether-lumefantrine, Malar J, vol.11, p.420, 2012.

C. O. Falade, Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children, Malar J, vol.7, p.246, 2008.

S. Duparc, Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials, Malar J, vol.12, p.70, 2013.

P. Jittamala, Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects, Antimicrob Agents Chemother, vol.59, pp.505-518, 2015.

C. A. Morris, Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers, Am J Trop Med Hyg, vol.86, pp.489-95, 2012.

J. F. Wernicke, D. Faries, R. Breitung, and D. Girod, QT correction methods in children and adolescents, J Cardiovasc Electrophysiol, vol.16, pp.76-81, 2005.

L. Roggelin, Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria, Malar J, vol.13, p.219, 2014.

J. A. Green, Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or ArtemetherLumefantrine in Healthy Adult Subjects, Antimicrob Agents Chemother, vol.60, pp.7321-7353, 2016.

V. Navaratnam, Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers, Eur J Clin Pharmacol, vol.65, pp.809-830, 2009.

C. Funck-brentano, Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation, Sci. Rep
URL : https://hal.archives-ouvertes.fr/hal-02018103

D. Q. Phan, M. J. Silka, Y. T. Lan, and R. K. Chang, Comparison of formulas for calculation of the corrected QT interval in infants and young children, J Pediatr, vol.166, pp.1-2, 2015.

X. H. Chan, Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis, Lancet Infect Dis, vol.18, pp.913-936, 2018.

P. Millat-martinez and Q. Bassat, Reappraising the cardiosafety of dihydroartemisinin-piperaquine, Lancet Infect Dis, vol.18, pp.824-830, 2018.